Ribometrix

The Full Promise of RNA-Targeted Drugs

Durham, United States · Founded 2014 · $45.3M raised

Employees
11–50
Founded
2014
Business Model
B2B
Total Funding
$45.3M
Last Round
$7.8M Venture RoundSep 2019
Rounds
3

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Ribometrix is a biotechnology company that develops small molecule drugs designed to directly target cellular RNAs and thereby correct the levels of the disease-causing proteins those RNAs encode, combining approaches from conventional small-molecule and oligonucleotide-based drug discovery. Headquartered in the heart of North Carolina's Research Triangle Park, the company has built what it calls the leading industry platform for discovering and developing RNA-targeting small molecule therapeutics, working with strategic partners to advance this new therapeutics frontier.

Summary

Ribometrix is a Biotech company based in Durham, United States, founded in 2014. It has raised $45.3M in total across 3 rounds, most recently a $7.8M Venture Round in Sep 2019. Investors include M Ventures, Illumina Ventures and Dementia Discovery Fund.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Venture RoundVenture RoundSep 2019
$7.8M

Sign up to see all 3 events

Funding: Seed through Venture Round. Amounts, valuations, and investors where available.

Investors

Similar Companies

AsymchemIPO

Asymchem is a pharmaceutical CDMO providing R&D, chemistry, manufacturing, and control services t...

Tianjin, China5001–10000Biotech, Drug Discovery
Private EquityTotal funding$2.3BFeb 2020
Abogen Biosciences

Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...

Suzhou, China201–500Biotech, Drug Discovery
Extension RoundTotal funding$1.2BNov 2021
Eikon TherapeuticsIPO

Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...

Hayward, United States201–500Artificial Intelligence, Biotech
Series DTotal funding$1.1BFeb 2025
Xaira Therapeutics

Xaira Therapeutics is an integrated biotechnology company driving advances in artificial intellig...

South San Francisco, United States51–200Artificial Intelligence, Biotech
Series ATotal funding$1.0BApr 2024
Treeline Biosciences

Clinical-stage biopharma developing precision medicines for cancer and other serious diseases usi...

Watertown, United States51–200Biotech, Drug Discovery
Extension RoundTotal funding$821.8MSep 2025
LifeMine

Therapeutics company working in drug discovery and development using fungi with genomics approach...

Watertown, United States51–200Biotech, Drug Discovery
Venture RoundTotal funding$816.0MAug 2026

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Ribometrix on Indexed.vc
<a href="https://indexed.vc/companies/ribometrix"><img src="https://indexed.vc/api/badge/company/ribometrix" alt="Ribometrix on Indexed.vc" width="260" height="76" /></a>